Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.

Baker LCJ, Sikka A, Price JM, Boult JKR, Lepicard EY, Box G, Jamin Y, Spinks TJ, Kramer-Marek G, Leach MO, Eccles SA, Box C, Robinson SP.

Front Oncol. 2018 Jul 23;8:271. doi: 10.3389/fonc.2018.00271. eCollection 2018.

2.

Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology.

Little RA, Jamin Y, Boult JKR, Naish JH, Watson Y, Cheung S, Holliday KF, Lu H, McHugh DJ, Irlam J, West CML, Betts GN, Ashton G, Reynolds AR, Maddineni S, Clarke NW, Parker GJM, Waterton JC, Robinson SP, O'Connor JPB.

Radiology. 2018 Sep;288(3):739-747. doi: 10.1148/radiol.2018171531. Epub 2018 Jun 5.

3.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

4.

Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model.

Hill DK, Heindl A, Zormpas-Petridis K, Collins DJ, Euceda LR, Rodrigues DN, Moestue SA, Jamin Y, Koh DM, Yuan Y, Bathen TF, Leach MO, Blackledge MD.

Front Oncol. 2017 Dec 1;7:290. doi: 10.3389/fonc.2017.00290. eCollection 2017.

5.

Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging.

Shah A, Delgado-Goni T, Casals Galobart T, Wantuch S, Jamin Y, Leach MO, Robinson SP, Bamber J, Beloueche-Babari M.

Sci Rep. 2017 Aug 15;7(1):8215. doi: 10.1038/s41598-017-07864-8.

6.

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.

Almeida GS, Panek R, Hallsworth A, Webber H, Papaevangelou E, Boult JK, Jamin Y, Chesler L, Robinson SP.

Br J Cancer. 2017 Sep 5;117(6):791-800. doi: 10.1038/bjc.2017.251. Epub 2017 Aug 8.

7.

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L.

Mol Oncol. 2017 Aug;11(8):996-1006. doi: 10.1002/1878-0261.12069. Epub 2017 May 31.

8.

Investigating the Vascular Phenotype of Subcutaneously and Orthotopically Propagated PC3 Prostate Cancer Xenografts Using Combined Carbogen Ultrasmall Superparamagnetic Iron Oxide MRI.

Burrell JS, Walker-Samuel S, Boult JK, Baker LC, Jamin Y, Halliday J, Waterton JC, Robinson SP.

Top Magn Reson Imaging. 2016 Oct;25(5):237-243. Review.

9.

Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma.

Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M.

Cancer Cell. 2016 Aug 8;30(2):357-358. doi: 10.1016/j.ccell.2016.07.002. Epub 2016 Aug 8. No abstract available.

10.

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.

Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B.

Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7.

11.

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, Workman P, Chesler L.

Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544.

12.

p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.

Yogev O, Barker K, Sikka A, Almeida GS, Hallsworth A, Smith LM, Jamin Y, Ruddle R, Koers A, Webber HT, Raynaud FI, Popov S, Jones C, Petrie K, Robinson SP, Keun HC, Chesler L.

Cancer Res. 2016 May 15;76(10):3025-35. doi: 10.1158/0008-5472.CAN-15-1939. Epub 2016 Mar 29.

13.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Osborne JD, Matthews TP, McHardy T, Proisy N, Cheung KM, Lainchbury M, Brown N, Walton MI, Eve PD, Boxall KJ, Hayes A, Henley AT, Valenti MR, De Haven Brandon AK, Box G, Jamin Y, Robinson SP, Westwood IM, van Montfort RL, Leonard PM, Lamers MB, Reader JC, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I.

J Med Chem. 2016 Jun 9;59(11):5221-37. doi: 10.1021/acs.jmedchem.5b01938. Epub 2016 May 23.

14.

Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models.

O'Connor JP, Boult JK, Jamin Y, Babur M, Finegan KG, Williams KJ, Little RA, Jackson A, Parker GJ, Reynolds AR, Waterton JC, Robinson SP.

Cancer Res. 2016 Feb 15;76(4):787-95. doi: 10.1158/0008-5472.CAN-15-2062. Epub 2015 Dec 9.

15.

Diffusion-weighted MRI for early detection and characterization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model.

Hill DK, Kim E, Teruel JR, Jamin Y, Widerøe M, Søgaard CD, Størkersen Ø, Rodrigues DN, Heindl A, Yuan Y, Bathen TF, Moestue SA.

J Magn Reson Imaging. 2016 May;43(5):1207-17. doi: 10.1002/jmri.25087. Epub 2015 Nov 11.

PMID:
26559017
16.

Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.

Dolman ME, Poon E, Ebus ME, den Hartog IJ, van Noesel CJ, Jamin Y, Hallsworth A, Robinson SP, Petrie K, Sparidans RW, Kok RJ, Versteeg R, Caron HN, Chesler L, Molenaar JJ.

Clin Cancer Res. 2015 Nov 15;21(22):5100-9. doi: 10.1158/1078-0432.CCR-15-0313. Epub 2015 Jul 22.

17.

Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.

Papaevangelou E, Almeida GS, Jamin Y, Robinson SP, deSouza NM.

Br J Cancer. 2015 Apr 28;112(9):1471-9. doi: 10.1038/bjc.2015.134. Epub 2015 Apr 16.

18.

Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography.

Jamin Y, Boult JKR, Li J, Popov S, Garteiser P, Ulloa JL, Cummings C, Box G, Eccles SA, Jones C, Waterton JC, Bamber JC, Sinkus R, Robinson SP.

Cancer Res. 2015 Apr 1;75(7):1216-1224. doi: 10.1158/0008-5472.CAN-14-1997. Epub 2015 Feb 11.

19.

Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.

Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP.

PLoS One. 2014 Mar 25;9(3):e92886. doi: 10.1371/journal.pone.0092886. eCollection 2014.

20.

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography.

Li J, Jamin Y, Boult JK, Cummings C, Waterton JC, Ulloa J, Sinkus R, Bamber JC, Robinson SP.

Br J Cancer. 2014 Apr 2;110(7):1727-32. doi: 10.1038/bjc.2014.76. Epub 2014 Feb 25.

21.

Model free approach to kinetic analysis of real-time hyperpolarized 13C magnetic resonance spectroscopy data.

Hill DK, Orton MR, Mariotti E, Boult JK, Panek R, Jafar M, Parkes HG, Jamin Y, Miniotis MF, Al-Saffar NM, Beloueche-Babari M, Robinson SP, Leach MO, Chung YL, Eykyn TR.

PLoS One. 2013 Sep 4;8(9):e71996. doi: 10.1371/journal.pone.0071996. eCollection 2013.

22.

Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance.

Jamin Y, Eykyn TR, Poon E, Springer CJ, Robinson SP.

Mol Imaging Biol. 2014 Apr;16(2):152-7. doi: 10.1007/s11307-013-0680-5.

23.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Beloueche-Babari M, Jamin Y, Arunan V, Walker-Samuel S, Revill M, Smith PD, Halliday J, Waterton JC, Barjat H, Workman P, Leach MO, Robinson SP.

Br J Cancer. 2013 Sep 17;109(6):1562-9. doi: 10.1038/bjc.2013.456. Epub 2013 Aug 13.

24.

Evaluation and immunohistochemical qualification of carbogen-induced ΔR₂ as a noninvasive imaging biomarker of improved tumor oxygenation.

Baker LC, Boult JK, Jamin Y, Gilmour LD, Walker-Samuel S, Burrell JS, Ashcroft M, Howe FA, Griffiths JR, Raleigh JA, van der Kogel AJ, Robinson SP.

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):160-7. doi: 10.1016/j.ijrobp.2013.04.051. Epub 2013 Jul 9.

PMID:
23849692
25.

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.

Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M.

Cancer Cell. 2013 Jul 8;24(1):75-89. doi: 10.1016/j.ccr.2013.05.005. Epub 2013 Jun 20. Erratum in: Cancer Cell. 2016 Aug 8;30(2):357-358.

26.

¹H NMR and hyperpolarized ¹³C NMR assays of pyruvate-lactate: a comparative study.

Hill DK, Jamin Y, Orton MR, Tardif N, Parkes HG, Robinson SP, Leach MO, Chung YL, Eykyn TR.

NMR Biomed. 2013 Oct;26(10):1321-1325. doi: 10.1002/nbm.2957. Epub 2013 May 27.

27.

Exploring ΔR(2) * and ΔR(1) as imaging biomarkers of tumor oxygenation.

Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Halliday J, Waterton JC, Robinson SP.

J Magn Reson Imaging. 2013 Aug;38(2):429-34. doi: 10.1002/jmri.23987. Epub 2013 Jan 4.

PMID:
23293077
28.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP.

Radiology. 2013 Jan;266(1):130-40. doi: 10.1148/radiol.12120128. Epub 2012 Nov 20.

29.

CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, Hallsworth A, Smith EL, Boxall KJ, Lainchbury M, Matthews TP, Jamin Y, Robinson SP, Aherne GW, Reader JC, Chesler L, Raynaud FI, Eccles SA, Collins I, Garrett MD.

Clin Cancer Res. 2012 Oct 15;18(20):5650-61. doi: 10.1158/1078-0432.CCR-12-1322. Epub 2012 Aug 28.

30.

MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting.

Burrell JS, Bradley RS, Walker-Samuel S, Jamin Y, Baker LC, Boult JK, Withers PJ, Halliday J, Waterton JC, Robinson SP.

Microvasc Res. 2012 Nov;84(3):323-9. doi: 10.1016/j.mvr.2012.08.001. Epub 2012 Aug 18.

31.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE.

Cancer Cell. 2012 Jul 10;22(1):117-30. doi: 10.1016/j.ccr.2012.06.001.

32.

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.

Boult JK, Jamin Y, Jacobs V, Gilmour LD, Walker-Samuel S, Halliday J, Elvin P, Ryan AJ, Waterton JC, Robinson SP.

Br J Cancer. 2012 Jun 5;106(12):1960-6. doi: 10.1038/bjc.2012.208. Epub 2012 May 17.

33.

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Bielen A, Box G, Perryman L, Bjerke L, Popov S, Jamin Y, Jury A, Valenti M, Brandon Ade H, Martins V, Romanet V, Jeay S, Raynaud FI, Hofmann F, Robinson SP, Eccles SA, Jones C.

Proc Natl Acad Sci U S A. 2012 May 15;109(20):E1267-76. doi: 10.1073/pnas.1105034109. Epub 2012 Apr 23.

34.

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function.

Baker LC, Boult JK, Walker-Samuel S, Chung YL, Jamin Y, Ashcroft M, Robinson SP.

Br J Cancer. 2012 May 8;106(10):1638-47. doi: 10.1038/bjc.2012.131. Epub 2012 Apr 12.

35.

Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.

Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Jamin Y, Ryan AJ, Waterton JC, Halliday J, Robinson SP.

Int J Cancer. 2012 Oct 15;131(8):1854-62. doi: 10.1002/ijc.27460. Epub 2012 Mar 22.

36.

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S.

Mol Cancer Ther. 2011 Nov;10(11):2115-23. doi: 10.1158/1535-7163.MCT-11-0333. Epub 2011 Sep 1.

37.

Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas.

Boult JK, Walker-Samuel S, Jamin Y, Leiper JM, Whitley GS, Robinson SP.

J Pathol. 2011 Nov;225(3):344-52. doi: 10.1002/path.2904. Epub 2011 May 18.

PMID:
21590769
38.

Noninvasive detection of carboxypeptidase G2 activity in vivo.

Jamin Y, Smyth L, Robinson SP, Poon ES, Eykyn TR, Springer CJ, Leach MO, Payne GS.

NMR Biomed. 2011 May;24(4):343-50. doi: 10.1002/nbm.1597. Epub 2010 Oct 3.

PMID:
20891022
39.

Hyperpolarized (13)C magnetic resonance detection of carboxypeptidase G2 activity.

Jamin Y, Gabellieri C, Smyth L, Reynolds S, Robinson SP, Springer CJ, Leach MO, Payne GS, Eykyn TR.

Magn Reson Med. 2009 Nov;62(5):1300-4. doi: 10.1002/mrm.22049.

40.

Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR.

Gabellieri C, Beloueche-Babari M, Jamin Y, Payne GS, Leach MO, Eykyn TR.

NMR Biomed. 2009 May;22(4):456-61. doi: 10.1002/nbm.1361.

PMID:
19156696

Supplemental Content

Support Center